[1]喻明洁,向荣风,熊丽蓉,等.雷诺嗪缓释片在中国健康人体内的药代动力学研究[J].第三军医大学学报,2019,41(02):177-182.
 YU Mingjie,XIANG Rongfeng,XIONG Lirong,et al.Pharmacokinetic study of ranolazine in Chinese healthy volunteers [J].J Third Mil Med Univ,2019,41(02):177-182.
点击复制

雷诺嗪缓释片在中国健康人体内的药代动力学研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第02期
页码:
177-182
栏目:
药学
出版日期:
2019-01-30

文章信息/Info

Title:
Pharmacokinetic study of ranolazine in Chinese healthy volunteers
 
作者:
喻明洁向荣风熊丽蓉李晓宇戴青陈勇川
陆军军医大学(第三军医大学)第一附属医院药剂科;解放军第980医院邯郸分院药剂科
Author(s):
YU Mingjie XIANG Rongfeng XIONG Lirong LI Xiaoyu DAI Qing CHEN Yongchuan

Department of Pharmacy, First Affiliated Hospital, Army Medical University(Third Military Medical University), Chongqing, 400038; Department of Pharmacy, Handan Branch of No. 980 Hospital of PLA, Handan, Hebei Province, 056001, China

关键词:
雷诺嗪缓释片高效液相色谱串联质谱药代动力学  
Keywords:
ranolazine sustained release tabletsHPLC-MS-MS pharmacokinetics
分类号:
R944.9; R969.1; R972.3
文献标志码:
A
摘要:

目的 评价雷诺嗪缓释片单次和多次口服给药后在中国健康人体内的药代动力学特征。方法 采用自身对照试验设计,单次、多次给药组各纳入10例健康受试者,男女各半,单次分3个周期依次服用500、1 000、1 500 mg雷诺嗪缓释片;多次分2个周期依次服用500、1 000 mg雷诺嗪缓释片;采用高效液相色谱串联质谱(LCMSMS)法测定血浆样品中雷诺嗪的浓度,计算主要药代动力学参数。结果 血浆中雷诺嗪浓度线性范围为40~4 000 μg/L,定量下限为40 μg/L,批内、批间精密度均小于15%。单次给药3个不同剂量(500、1 000、1 500 mg)的Cmax分别为(774±157)、(1 818±554)、(2 762±1 099)μg/L;tmax分别为(4.9±1.8)、(4.9±2.6)、(4.9±1.5)h;t1/2z分别为(8.2±6.8)、(10.3±8.7)、(9.7±12.0)h;AUC0-t分别为(8 470±2 765)、(20 936±6 957)、(32 554±17 780)μg·h/L。多次给药2个不同剂量(500、1 000 mg)Cmaxss分别为(1 826±904)、(3 635±620)μg/L;Cminss分别为(1 022±3)、(2 282±163)μg/L;Cav分别为(1 253±634)、(2 615±536)μg/L;AUC0t分别为(22 452±12 359)、(53 232±15 909)μg·h/L;MRT0-t分别为(8.7±2.3)、(10.6±2.6);RAUC分别为(3.11±2.60)、(2.86±1.54)。结论 在单次给药试验中Cmax和AUC与剂量呈比例增加,且3个给药剂量有很好的线性关系;多次给药试验发现雷诺嗪在健康人体内有一定的积累。

Abstract:

Objective To evaluate pharmacokinetics after administration of ranolazine sustained release tablets at a single and multiple dose to healthy Chinese volunteers. Methods A self-controlled trial design was used. In the single-time group, 10 healthy volunteers, half male and half female,  were included, and 500, 1 000 and 1 500 mg ranolazine sustained-release tablets were taken sequentially in 3 cycles. For the multiple-dose group, 10 individuals of both sexes were enrolled, and 500 and 1 000 mg ranolazine sustainedrelease tablets were sequentially administered in 2 cycles. The concentration of ranolazine in plasma samples was determined by LC-MS-MS, and the main pharmacokinetic parameters were calculated. Results The linear concentration of ranolazine in plasma ranged from 40 to 4 000 μg/L, and the LLOQ was 40 μg/L. The intra-assay and inter-assay precision were less than 15%. After single dose, the main parameters in doses 500,1 000,1 500 mg were Cmax: 774±157, 1 818±554 and 2 762±1 099 μg/L,respectively; tmax: 4.9±1.8, 4.9±2.6 and 4.9±1.5 h, respectively; t1/2z: 8.2±6.8, 10.3±8.7 and 9.7±12.0 h, respectively; AUC0-t: 8 470±2 765, 20 936±6 957 and 32 554±17 780 μg·h/L, respectively. After multiple dose, the main parameters in doses 500,1 000 mg were Cmaxss:  1 826±904 and 3 635±620 μg/L; Cminss: 1 022±3 and 2 282±163 μg/L; Cav:  1 253±634 and 2 615±536 μg/L; AUC0-t: 22 452±12 359 and 53 232±15 909 μg·h/L; MRT0-t: 8.7±2.3 and 10.6±2.6; RAUC: 3.11±2.60 and 2.86±1.54. Conclusion In a single administration trial, Cmax and AUC are increased proportionally to the dose, and there is a good linear relationship between the three doses. Multiple dose tests have found that ranolazine has a certain accumulation in the body.

参考文献/References:

[1]CODOLOSA J N, ACHARJEE S, FIGUEREDO V M. Update on ranolazine in the management of angina[J]. Vasc Health Risk Manag, 2014, 10: 353-362. DOI: 10.2147/VHRM.S40477.
[2]SIDDIQUI M A, KEAM S J. Ranolazine: a review of its use in chronic stable angina pectoris[J].Drugs, 2006, 66(5): 693-710. DOI: 10.2165/00003495-200666050-00010.
[3]ROSANO G M C, VITALE C, VOLTERRANI M.Pharmacological management of chronic stable angina focus on ranolazine [J]. Cardiovasc Drugs Ther, 2016, 30(4): 393-398.DOI: 10.1007/s10557-016-6674-1.
[4]FUMAGALLI F, RUSSO I, STASZEWSKY L, et al. Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest[J]. Heart Rhythm, 2014, 11(9): 1641-1647. DOI: 10.1016/j.hrthm.2014.05.023.
[5]FRAGAKIS N, KOSKINAS K C, VASSILIKOS V. Ranolazine as a promising treatment option for atrial fibrillation electrophysiologic mechanisms experimental evidence, and clinical implications[J]. Pacing Clin Electrophysiol, 2014, 37(10): 1412-1420. DOI: 10.1111/pace.12486.
[6]JERLING M. Clinical pharmacokinetics of ranolazine[J]. Clin Pharmacokinet, 2006, 45(5): 469-491. DOI: 10.2165/00003088-200645050-00003.
[7]贾晶莹, 刘罡一, 陈钧, 等. 高效液相色谱法测定犬血浆中雷诺嚓的含量及相对生物利用度[J]. 中国新药与临床杂志, 2011, 30(7): 537-540.
JIA J Y, LIU G Y, CHEN J, et al.Determination of ranolazine in Beagle dog plasma by HPLC-UV method[J].Chin J New Drugs Clin Rem, 2011, 30(7): 537-540.
[8]TIAN L, JIANG J, HUANG Y, et al. Sensitive quantification of ranolazine in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionization[J]. J Chromatogr B, 2007, 846(1): 346-350. DOI: 10.1016/j.jchromb.2006.08.010.
[9]王志宏, 李扬, 侯文静, 等. 雷诺嗪缓释片在中国健康受试者中的药动学研究[J]. 中国药学杂志, 2014, 49(6): 496-500. DOI: 10.11669/cpj.2014.06.014.
WANG Z H, LI Y, HOU W J, et al.Pharmacokinetic study of ranolazine in Chinese healthy volunteers[J]. Chin Pharm J, 2014, 49(6): 496-500. DOI: 10.11669/cpj.2014.06.014.
[10]TAN Q Y, ZHU R H, LI H D, et al. Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 901: 119-124. DOI: 10.1016/j.jchromb.2012.06.011.
[11]MASTERS J C, SHAH M M, FEIST A A. Drug interaction between sirolimus and ranolazine in a kidney transplant patient[J]. Case Rep Transplant, 2014, 2014: 548243. DOI: 10.1155/2014/5482432.
[12]谭亲友, 朱荣华, 李焕德, 等. HPLC-MS/MS法测定雷诺嗪血药浓度及其缓释制剂的药代动力学研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 549-553.
TAN Q Y, ZHU R H, LI H D, et al. Quantification of Ranolazine in human plasma using HPLC-MS/MS for pharmacokinetic study of its sustainedrelease preparation[J].Chin J Clin Pharmacol Ther, 2012, 17(5): 549-553.
 

相似文献/References:

[1]陈勇川,何菊英,唐敏,等.盐酸二甲双胍缓释片人体相对生物利用度及其药代动力学研究[J].第三军医大学学报,2005,27(21):2148.
[2]陈代勇,臧志和,杨万青,等.贝诺酯缓释骨架片释药速率影响因素实验研究[J].第三军医大学学报,2004,26(14):0.[doi:10.16016/j.1000-5404.2004.14.018 ]
 CHEN Dai yong,ZANG Zhi he,YANG Wan qing,et al.[J].J Third Mil Med Univ,2004,26(02):0.[doi:10.16016/j.1000-5404.2004.14.018 ]

更新日期/Last Update: 2019-01-30